Drug interactions
C1 esterase inhibitor + Lanadelumab
Severity: Minor
C1 esterase inhibitor and Lanadelumab: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
C1 esterase inhibitor is used as rescue therapy for breakthrough hereditary angioedema attacks in patients on lanadelumab. Both act on the contact-kallikrein pathway, but no pharmacokinetic interaction is expected and the combination is clinically intended.
What this interaction means in plain words
C1 esterase inhibitor and Lanadelumab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
C1 esterase inhibitor belongs to Miscellaneous; Lanadelumab belongs to Miscellaneous.
Why it happens
Complementary pharmacodynamic inhibition of the kallikrein-kinin pathway; no pharmacokinetic interaction expected.
What to do
Use C1 esterase inhibitor as on-demand treatment of breakthrough attacks as needed and record attack frequency to assess lanadelumab response.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for C1 esterase inhibitor and Lanadelumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Frequently asked questions
Can I take C1 esterase inhibitor with Lanadelumab?
MediHelp rates the interaction as minor. C1 esterase inhibitor and Lanadelumab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. C1 esterase inhibitor is used as rescue therapy for breakthrough hereditary angioedema attacks in patients on lanadelumab. Both act on the contact-kallikrein pathway, but no pharmacokinetic interaction is expected and the combination is clinically intended.
How serious is the interaction between C1 esterase inhibitor and Lanadelumab?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Use C1 esterase inhibitor as on-demand treatment of breakthrough attacks as needed and record attack frequency to assess lanadelumab response.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
